67.55
0.14 (0.22%)
| Penutupan Terdahulu | 67.41 |
| Buka | 67.58 |
| Jumlah Dagangan | 2,485,840 |
| Purata Dagangan (3B) | 2,469,901 |
| Modal Pasaran | 13,230,428,160 |
| Harga / Jualan (P/S) | 22.37 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Aug 2026 |
| Margin Operasi (TTM) | -89.00% |
| EPS Cair (TTM) | -3.56 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -44.80% |
| Nisbah Semasa (MRQ) | 4.57 |
| Aliran Tunai Operasi (OCF TTM) | -500.42 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -261.20 M |
| Pulangan Atas Aset (ROA TTM) | -48.27% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | BridgeBio Pharma, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.00 |
|
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 4.97% |
| % Dimiliki oleh Institusi | 98.14% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Aisling Capital Management Lp | 31 Mar 2026 | 5,089,611 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |